阿托伐他汀钙片和瑞舒伐他汀钙片用于冠心病经皮冠状动脉介入治疗术后患者的临床研究  

Clinical trial of atorvastatin calcium tablets and rosuvastatin calcium tablets in the treatment of patients with myocardial infarction after percutaneous coronary intervention

作　　者：王增帅[1] 冯彩霞[2] 赵志先 薛开成[1] 谢瑞[1] WANG Zeng-shuai;FENG Cai-xia;ZHAO Zhi-xian;XUE Kai-cheng;XIE Rui(Department of Cardiology,Second Affiliated Hospital of Baotou Medical College of Inner Mongolia University of Science and Technology,Baotou 014030,Inner Mongolia Autonomous Region,China;Department of Neurology,Second Affiliated Hospital of Baotou Medical College of Inner Mongolia University of Science and Technology,Baotou 014030,Inner Mongolia Autonomous Region,China)

机构地区：[1]内蒙古科技大学包头医学院第二附属医院心脏内科,内蒙古自治区包头014030 [2]内蒙古科技大学包头医学院第二附属医院神经内科,内蒙古自治区包头014030

出　　处：《中国临床药理学杂志》2020年第15期2168-2171,共4页The Chinese Journal of Clinical Pharmacology

基　　金：包头医学院科学研究基金项目扬帆计划资助项目(BYJJ-YF201630)。

摘　　要：目的比较阿托伐他汀钙片和瑞舒伐他汀钙片用于冠心病经皮冠状动脉介入治疗(PCI)患者的临床疗效及安全性。方法将157例患者随机分为对照组78例和试验组79例。对照组给予瑞舒伐他汀钙片每次10 mg,每晚1次,口服;试验组给予阿托伐他汀钙片每次20 mg,每晚1次,口服。2组患者均连续给药6个月。比较2组患者的血脂、颈动脉斑块总积分,以及药物不良反应的发生情况。结果治疗后6个月,试验组和对照组的总胆固醇分别为(3.54±0.86)和(3.11±0.58)mmol·L^-1,低密度脂蛋白胆固醇分别为(2.08±0.54)和(1.74±0.35)mmol·L^-1,差异均有统计学意义(均P<0.05)。试验组治疗前和治疗后6个月的颈动脉斑块总积分分别为(8.27±4.63)和(7.48±3.47)mm,差异有统计学意义(P<0.05)。2组患者的药物不良反应均以肌酶升高、肌肉疼痛和肝酶升高为主。试验组和对照组的总药物不良反应发生率分别为4.84%和7.02%,差异无统计学意义(P>0.05)。结论阿托伐他汀钙片能显著降低冠心病PCI患者的颈动脉斑块总积分,且不增加药物不良反应的发生率。Objective To compare the clinical efficacy and safety of atorvastatin calcium tablets and rosuvastatin calcium tablets in the treatment of patients with myocardial infarction after percutaneous coronary intervention(PCI).Methods A total of 157 patients with myocardial infarction after PCI were randomly divided into control group(n=78 cases)and treatment group(n=79 cases).Control group was given rosuvastatin calcium 10 mg per time,once a night,orally.Treatment group received atorvastatin calcium 20 mg per time,once a night,orally.Two groups were treated for 6 months.The blood lipid,total carotid plaque scores and adverse drug reactions were compared between two groups.Results After 6 months treatment,the main indexes of treatment and control groups were compared:the total cholesterol were(3.54±0.86)and(3.11±0.58)mmol·L^-1,low density lipoprotein cholesterol were(2.08±0.54)and(1.74±0.35)mmol·L^-1,the differences were statistically significant(all P<0.05).The total score indexes of carotid artery plaque in the treatment group before treatment and 6 months after treatment were(8.27±4.63)and(7.48±3.47)mm,the differences were statistically significant(P<0.05).The adverse drug reactions of two groups were muscle enzyme elevation,muscle pain and liver enzyme elevation.The total incidences of adverse drug reactions in the treatment and control groups were 4.84% and 7.02% without significant difference(P>0.05).Conclusion Atorvastatin calcium tablets have a definitive clinical efficacy in the treatment of patients with myocardial infarction after PCI,which can significantly reduce the patients’total carotid plaque score,without increasing the incidence of adverse drug reactions.

关 键 词：阿托伐他汀钙片 瑞舒伐他汀钙片 冠心病 经皮冠状动脉介入治疗 安全性评价 

分 类 号：R972[医药卫生—药品]